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Abstract 
Background - Major depressive disorder and sub-threshold depression have been associated 
with premature mortality. We investigated the association between depressive symptoms and 
mortality across the full continuum of severity.  
Methods - We used Cox proportional hazards models to examine the association between 
depressive symptom severity, assessed using the eight-item Center for Epidemiological 
Studies Depression Scale (CES-D; range of 0 to 8), and the risk of all-cause mortality over a 
9-year follow-up, in 11,104 members of The English Longitudinal Study of Ageing. 
Results – During following up, one fifth of study members died (N=2,267). Depressive 
symptoms were associated with increased mortality across the full range of severity (P for 
trend <0.001). Relative to study members with no symptoms, an increased risk of mortality 
was found in people with depressive symptoms of a low (hazard ratio (HR) for a score of two 
was 1.59; 95% confidence interval (CI) = 1.40, 1.82), moderate (four: HR = 1.80; 95% CI = 
1.52, 2.13) and high severity (eight: HR = 2.27; 95% CI = 1.69, 3.04), suggesting risk 
emerges at low levels but plateaus thereafter. A third of participants (36.4%; 95% CI 35.5%, 
37.3%) reported depressive symptoms associated with an increased mortality risk. 
Adjustment for physical activity, physical illnesses, and impairments in physical and 
cognitive functioning attenuated this association (P for trend = 0.25).  
Conclusions - Depressive symptoms are associated with an increased mortality risk even at 
low-levels of symptom severity. This association is explained by physical activity, physical 
illnesses, and impairments in physical and cognitive functioning. 
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Introduction 
Several systematic reviews have shown that a diagnosis of major depressive disorder 
(Cuijpers et al. 2013; Cuijpers & Smit 2002; Saz & Dewey 2001), minor depression (Saz & 
Dewey 2001), and screening positive for ‘caseness’ on self-report scales of depressive 
symptoms (Cuijpers et al. 2013; Saz & Dewey 2001) are associated with an elevated risk of 
mortality. In the few studies which have examined depressive symptoms across the full 
continuum of severity, an increased risk of mortality has emerged in some at moderate levels 
of depressive symptom severity (Almeida et al. 2010; Scafato et al. 2012; Schoevers et al. 
2009), whereas in others risk is only elevated in people with more severe symptoms 
(Everson-Rose et al., 2004; Ryan et al. 2008; van den Brink et al. 2005; Wulsin et al. 2005). 
In all of these studies, scores on the severity of depressive symptoms were collapsed into a 
small number of categories, (Almeida et al. 2010; Everson-Rose et al. 2004; Ryan et al. 
2008; Scafato et al. 2012; Schoevers et al. 2009; van den Brink et al. 2005; Wulsin et al. 
2005), so limiting insights into the “shape” of the depressive symptom-mortality relation (i.e., 
dose-response versus threshold). 
 
We undertook an analysis of the association between depressive symptoms and mortality 
across the full range of severity of depressive symptoms in the English Longitudinal Study of 
Ageing, a large, well-characterized, community-based cohort study of older adults. We 
hypothesized that the association between depressive symptoms and the risk of all-cause 
mortality would emerge at a severity below current thresholds for identifying clinically 
relevant symptoms of depression.  
 
Methods 
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We used data from the English Longitudinal Study of Ageing (ELSA). Initiated in 2002/3, 
ELSA is an on-going, longitudinal, biannual, nationally representative, prospective cohort 
study of health and ageing (Mindell et al. 2012). It is derived from adults aged 50 years of 
age or older who had earlier participated in the Health Survey for England (HSE) in 1998, 
1999, and 2001. Comparisons of the social and demographic characteristics of participants 
with the national census show that this sample was representative of the English population 
(Steptoe et al. 2013). We excluded 287 participants who did not give consent to link to the 
mortality records, resulting in a sample of 11,104 study members (6,054 women and 5,050 
men). Ethical approval for the ELSA was given by the National Research Ethics Service 
(MREC/01/2/91). 
 
Measurement of Depressive Symptoms  
During the 2002/03 household visit, information was collected on depressive symptoms using 
a computer assisted personal interview. Depressive symptoms were measured using the eight-
item Center for Epidemiological Studies-Depression scale (CES-D; Radloff 1977; Turvey et 
al. 1999). Used in the Health and Retirement Study (Steffick & the HRS Health Working 
Group. 2000) and other population-based studies (Radloff 1977; Turvey et al. 1999), the 
CES-D captures information on depressive symptoms and somatic complaints experienced in 
the past week (see supplementary information for individual scale items). A dichotomous 
(yes/no) response to each item results in a total score of between zero (no symptoms) and 
eight (most severe symptoms). This short version has good internal consistency (Cronbach’s 
α >0.95) and has comparable psychometric properties to the full 20-item CES-D (Radloff 
1977; Turvey et al. 1999). A total CES-D score of three or more (Turvey et al. 1999) or four 
or more (Steffick & the HRS Health Working Group. 2000) has been used to denote 
“caseness”. These thresholds have been validated against standardized psychiatric interviews 
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for depression in older adults, and are equivalent to the conventional demarcation point of 16 
or more on the full 20-item CES-D (Steffick & the HRS Health Working Group. 2000; 
Turvey et al. 1999). 
 
Measurement of Covariates 
From the 2002/3 interview we obtained information on social, demographic, clinical, and 
lifestyle covariates using a computer assisted personal interview. Socioeconomic position 
was based on the National Statistics Socio-economic Classification (NS-SEC) classification 
system (Rose & Pevalin 2003). A wealth score was based on the sum of all financial, physical 
(businesses, land) and housing wealth, minus debts and pension payments (Banks et al. 
2006).  Cohabitation status was defined as currently living alone or not. Self-reported health 
behaviors included smoking status (current, ex-smoker, and never), frequency of alcohol 
consumption in the past year (not at all, on special occasions, once or twice a month, once or 
twice a week, daily, ≥ 2 times a day), and physical activity during leisure time, recorded as 
participation in vigorous, moderate, and mild activities (more than once per week, once per 
week, one to three times per month, hardly ever) (Hamer et al. 2009). 
Measures of health included lifetime self-reported doctor diagnoses of chronic 
somatic conditions (chronic obstructive pulmonary disorder [COPD], asthma, diabetes, and 
arthritis), circulatory disease (hypertension, prior heart attack, stroke, angina), heart 
conditions (murmur, abnormal heart rhythm), depression and cancer. The use of 
antidepressants was recorded at wave 0 (HSE interviews in 1998, 1999 and 2001). Cognitive 
function was assessed using a test of memory and executive function (Steel et al. 2004). 
Functional impairments were assessed by asking participants whether they experienced 
difficulties, for at least three months, with six activities of daily living (ADL) and seven 
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instrumental activities of daily living (IADL; Steel et al. 2004). Participants reporting one or 
more problems with an ADL or IADL were classified as having a functional impairment. 
 
Mortality ascertainment 
All-cause mortality was ascertained for a nine year period for consenting study members 
(11,104; 97.5% of eligible participants) by linking to the UK National Health Service 
mortality register up to until the 15th March 2012. In the UK, registration of death within 5 
days is a legal requirement so participants not registered as dead were assumed to be alive.  
 
Statistical Analysis 
The characteristics of participants were compared according to the severity of their 
depressive symptoms using the chi-square test and analysis of variance. We then used Cox 
proportional hazards models (Cox 1972), with accompanying 95% confidence intervals, to 
estimate the association between depressive symptoms and mortality. We ascertained that the 
proportional hazards assumption had not been violated by inspecting the log (−log(survival)) 
plot and Schoenfeld residuals. Participants scoring 0 on the CES-D were regarded as being 
free of depressive symptoms and this was our reference group. We compared this reference 
group with those participants scoring in each of the remaining eight groups, plotted Kaplan-
Meier survival curves for each group, and also reported HRs per standard deviation increase 
in depressive symptoms (standard deviation: 2.00).   
Survival time was measured in months from the date of interview to date of death or 
the 15th March 2012 – which ever came first. Emigrants were included in analyses with the 
date of their last interview as their censoring date. In preliminary analyses, there was no 
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evidence that the association between depressive symptoms and mortality was modified by 
sex, so data for men and women were pooled and analyses sex-adjusted. We also took into 
account potentially important covariates, grouped according to  themes: basic model: age, sex 
and ethnicity; socioeconomic position, health behaviours, chronic conditions, circulatory 
disease, heart conditions, cancer, tests of cognitive function, any functional impairment, all 
diagnosed conditions, any antidepressant use reported in HSE interviews in 1998, 1999 and 
2001, and a fully adjusted model with all variables. As depression and cognitive function 
share symptoms (e.g. impaired concentration, fatigue) the adjustment for cognitive function 
could be considered an example of over adjustment. We therefore show models with and 
without the addition of cognitive function. The effect on the HR of adjusting for each set of 
covariates was estimated using the following formula ([HR basic model-1] – [HR adjusted 
model-1] / [HR basic model-1]) x 100% (Batty et al. 2006). 
 
Sensitivity Analysis 
We conducted several planned sensitivity analyses. We compared people with data missing 
for one or more variables with those with complete data using t-tests and the χ2 test. The 
proportion of missing data from item non-response was then imputed using multiple 
imputation by chained equations which included all variables (including mortality) in the 
prediction model using the ice command in Stata v.13 to generate 10 imputed datasets (White 
et al. 2011). To examine the effect of imputing data on the association between depressive 
symptoms and mortality we ran our analysis in a sample with no missing data (n= 10,131). In 
addition, we calculated a depressive symptom score after removing three items relating to 
somatic symptoms (see supplementary information for scale items), to examine if 
associations with mortality could be attributed to somatic complaints brought about by 
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physical illness, rather than depressive symptoms. To examine reverse cause, whereby 
somatic illness might have increased the risk of both depressive symptoms and death, we 
carried out sub-group analysis after excluding the 982 deaths that occurred within the first 
five years of follow-up. All analyses were conducted using Stata v.13. The reporting of this 
study conforms to the STROBE statement (von Elm et al. 2007).   
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Results 
Table 1 shows the characteristics of participants according to the severity of their depressive 
symptoms. The majority of people reported at least one depressive symptom (59.5%, 95% = 
58.7-60.5) and the mean symptom severity score was 1.68 (SD = 2.00; range 0-8; median = 
1.00; interquartile range 1.00 - 2.00). People reporting a greater severity of depressive 
symptoms were more likely to be female, older, non-white, employed in a routine occupation, 
have lower wealth, live alone, have impaired physical functioning, a smoker, hardly ever 
engage in physical activity, use anti-depressants, have lower memory and executive function 
scores, and report a doctor diagnosed health condition, than those with lower scores 
(P<0.001, table 1). There was also evidence that the highest levels of alcohol consumption 
were found in study members at opposing ends of the continuum of depressive symptoms.   
Of the 11,104 participants in the ELSA, 2,267 (20.4%) died during a mean follow-up 
of 9.1 years (SD = 2.3). Figure 1 shows a positive trend was found with more severe 
depressive symptoms associated with a higher rate of mortality (P for trend <0.001). After 
adjustment for socioeconomic position, the strength of the association between depressive 
symptoms and mortality (HR per one SD disadvantage) reduced from 1.26 in the basic model 
(age-, sex- and ethnicity-adjusted) to 1.20, representing 23% attenuation in risk. The greatest 
reduction in HRs occurred after adding health behaviors to the model (a 62% reduction 
compared to basic model), followed by functional impairments (54%) and physician 
diagnoses (23%), although after these separate adjustments the trend remained statistically 
significant the P <0.001 level. After full adjustment, the positive association between 
symptom severity and mortality was effectively eliminated (100% attenuation, P for trend= 
0.25, Figure 1 and Supplementary Table S1). Of the factors entered into the multivariable 
model, physical activity and functional impairments alone accounted for 73% of the 
depressive symptom-mortality association. 
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The unadjusted Kaplan Meir failure curve (Figure 2), 95% CIs for the HRs for a CES-
D score of 0 to 8 (Supplementary Table S1) and survival curve (Supplementary Figure S1) 
suggest there is a threshold in the association between depressive symptoms and mortality.  
Although the HRs increase with symptom severity there is not a statistically significant 
increase in risk after a score of two (log rank for a score of <2 vs. ≥2 = 2416.87; P<0.001). 
Figure 2 shows that by 70 years of age 10% of people with a depressive symptom score ≥2 
had died, a mortality rate that is not reached until age 75 years in those with a depressive 
symptom score <2. 
 
Sensitivity Analysis 
Data were missing for one or more variables for 8.8% (n=973) of the sample. 
Compared to those study members who featured in the analytical sample, people with 
missing data were more likely to be older, female, non-white, be in the lowest quintile for 
wealth, live alone, have had a heart attack, stroke, have diabetes, a heart condition, be 
inactive at mild, moderate or vigorous intensities, have a functional impairment, but less 
likely to drink heavily, or have smoked. However, no more likely to have angina, cancer, 
arthritis, COPD, asthma, be in a lower social class, or report using antidepressants. We 
examined the impact on our main estimates of missing data by repeating the analysis in 
participants without any missing data (n= 10,131). The results were comparable to those in 
the main analysis (age, sex- and ethnicity-adjusted HR per SD disadvantage with imputed 
data was 1.26, 95% CI = 1.22-1.31; the HR in sample without any missing data was 1.25, 
95% CI = 1.21-1.31; Supplementary Table S1 and S3). We also re-ran our analysis after 
removing items from the depressive symptom scale relating to somatic symptoms. The 
association between depressive symptoms and mortality was slightly attenuated after 
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removing somatic symptoms, but the trend remained significant (P<0.001, Supplementary 
Table S4).  
 
Sub-group analysis 
We excluded 982 deaths which occurred within the first five years of follow-up to test for 
reverse causality. These exclusions slightly reduced the strength of the association between 
depressive symptoms and mortality, but replicated the trend found in the main analysis 
(Supplementary Table S5). 
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Discussion 
The main finding in this study was an association between depressive symptoms across the 
full range of severity and all-cause mortality. We found that even in people with low to 
moderate symptom scores that they would not usually bring them to the attention of mental 
health services, experienced an increased risk of mortality. Excluding deaths occurring in the 
first five years of follow-up produced only a modest attenuation of the association suggesting 
it may be partially attributable to reverse cause. Adjustment for a wide range of potential 
confounding factors, including levels of physical inactivity, cognitive function, impairments 
and physical illnesses fully attenuated the association.  
We identified seven cohort studies that had examined the association between 
depressive symptoms across the continuum of severity and mortality (Almeida et al. 2010; 
Everson-Rose et al. 2004; Ryan et al. 2008; Scafato et al. 2012; Schoevers et al. 2009; van 
den Brink et al. 2005; Wulsin et al. 2005). Our results are broadly consistent with these 
studies, but comparisons are hampered by the wide variation in measures of depressive 
symptoms and the categorization of depressive symptom scores used. For example, we 
replicated the finding of a cohort of Australian men (Almeida et al. 2010) and the Italian 
Longitudinal Study of Ageing (Scafato et al. 2012) which both found the risk of mortality 
was raised at low levels of symptom severity on the Geriatric Depression Scale (GDS). 
However, as one used the 15-item (Almeida et al. 2010) and the other a 30-item version of 
the GDS (Scafato et al. 2012), and both collapsed symptom scores, the point at which 
mortality risk became elevated was unclear. Other investigators have found the risk of 
mortality to become raised in the highest tertile (Everson-Rose et al. 2004), or quintile (Ryan 
et al. 2008) of depressive symptom severity scores. Our findings do, however, replicate those 
of an individual-participant meta-analysis of the association between psychological distress, 
across the full range of symptoms severity and mortality (Russ et al. 2012).  
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The mechanism underpinning the association between the depressive symptoms and 
mortality is not well understood. To date, the most consistent pattern of attenuation of the 
association between depressive symptoms and all-cause mortality has been observed for 
physical illness (Houle 2013; Wulsin et al. 2005), functional impairments (Everson-Rose et 
al. 2004; Ganguli M et al. 2002), and health behaviors (Everson-Rose et al. 2004; Penninx 
BH 1999; Schulz et al. 2000; Wulsin et al. 2005). We replicated these findings, with 
functional impairments explaining 54% and health behaviors 62% of the association between 
depressive symptoms and mortality. In particular, physical activity and functional 
impairments alone explained 73% of this association. This pattern of attenuation is either 
consistent with confounding or mediation. It could be that inactivity and functional 
impairments increase depressive symptoms and the risk of mortality, suggesting confounding. 
Alternatively, as engaging in low levels of physical activity has been shown to slow the 
progression in mobility impairments (Miller et al. 2000), these factors could form part of an 
indirect mechanism which explains the association between depressive symptoms and 
mortality (Blazer et al. 2001). A recent analysis of the Americans’ Changing Lives Study 
provided partial support for a mediational hypothesis showing time-varying changes in 
physical illness and functional impairments mediated the association between baseline 
depressive symptoms and mortality; (Houle 2013) but changes in physical health conditions 
which preceded the assessment of depressive symptoms did not. Although randomized trials 
have shown mixed treatment effects of exercise on depression (Cooney et al. 2013), few have 
investigated whether treatments which are effective in reducing depressive symptoms also 
improve functional impairment and levels of physical activity. These studies should also 
assess whether these factors mediate any treatment effect on mortality.  
An alternative explanation is a direct effect, where depressive symptoms cause a 
physiological change which increases the risk of mortality. Depressive symptoms are 
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associated with elevated inflammatory markers, including levels of C-reactive protein, 
interleukin 6 (IL-6), and tumor necrosis factors (Dinan 2009). Injection with interferon-alpha 
(which increases cytokines and cortisol) (Gisslinger et al. 1993) has also been shown to elicit 
short-term increases in depressive symptoms (Capuron et al. 2003), and a meta-analysis of 22 
trials of antidepressants approved by the United States Food and Drug Administration 
showed a reduction in depressive symptoms was accompanied by a decrease in inflammatory 
cytokines after drug therapy (Hannestad et al. 2011). However, the use of antidepressants has 
also been associated with elevated C-reactive protein levels (Hamer et al. 2011) and an 
increased risk for cardiovascular disease independent of comorbidity (Hamer et al. 2010), 
such that the association between depressive symptoms, antidepressants and mortality is 
unclear. In the present study, adjustment for antidepressant had essentially no effect on risk 
estimates, suggesting antidepressant use is unlikely to explain the association between 
mortality and depressive symptoms.  
The main strength of this study is that it is with a nationally-representative sample, 
had a nine year follow-up, and detailed assessments of covariates. The large number of deaths 
(n = 2,267) allowed reverse causality to be investigated as a sufficient number of deaths 
remained after those occurring in the first five years of follow-up were excluded. The study 
also has some weaknesses. The CES-D although widely used in population-based studies is 
not without limitations. The scale only assesses symptoms in the past week, and does not 
provide a clinical diagnosis of major depression, even though there is evidence that screening 
positive on the eight-item CES-D we used is associated with a diagnosis of major depressive 
disorder (Steffick & the HRS Health Working Group. 2000; Turvey et al. 1999). Secondly, 
potentially important covariates such as adherence to psychological treatments (DiMatteo et 
al. 2000), diet and disease severity were not available. Whilst we did not directly measure 
disease severity, our measures of mobility and functional impairment are indicators of disease 
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severity, as they reflect the impact of multiple co-morbidities on the individual. If these 
factors were associated with depressive symptoms and mortality risk in a pattern which 
replicated the threshold we observed, the association may be due to confounding. Third, 
around 11% of participants had missing data for one or more variables; sensitivity analysis 
comparing the hazard ratios across complete case and imputed datasets showed no difference, 
suggesting bias introduced by missing data was minimal. Fourthly, as depressive symptoms 
are typically of a lower severity in people aged fifty to sixty years old than in younger 
populations (Sutin et al. 2013), these finding may not generalize to people aged under the age 
of fifty.  
In this large prospective study of men and women aged over 50 years, depressive 
symptoms were associated with an increased risk of mortality, even at low-levels of symptom 
severity. Levels of physical inactivity, cognitive function, functional impairments and 
physical illnesses fully attenuated this association. A third of older adults had symptoms at a 
severity associated with an increased risk for mortality, and one in ten scored under validated 
cut-points for clinically significant depressive symptoms but experienced an increased risk 
for all-cause mortality, suggesting current cut-points do not identify one in ten people at an 
increased risk for early death.   
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Table 1. Characteristics of 11,104 ELSA participants according to the severity of depressive symptoms 
 Depressive symptoms   
 0 
(None) 
1 2 3 4 5 6 7 8 
(highest) 
P-value 
for trend 
No. of participants  40.4 (4488) 23.2 (2578) 11.6 (1287) 8.1 (897) 5.6 (620) 4.2 (463) 3.1 (349) 2.2 (248) 1.6 (174)  
No. of deaths 15.1 (679) 17.6 (453) 26.9 (346) 28.7 (258) 28.5 (177) 29.6 (137) 29.2 (102) 26.2 (65) 28.7 (50) <0.001 
Age (Years), Mean (SD) 63.0 (9.36) 64.0 (9.9) 65.7 (10.7) 65.6 (10.6) 65.7 (10.1) 65.2 (10.5) 65.3 (10.9) 64.1 (10.9) 63.2 (109) <0.001 
Female  47.0 (2113) 57.1 (1472) 57.8 (744) 58.0 (521) 64.8 (402) 63.7 (295) 64.0 (223) 70.5 (174) 63.3 (110) <0.001 
Non-white ethnic group  1.8 (81) 2.4 (62) 2.8 (36) 3.2 (29) 3.5 (22) 6.0 (28) 4.3 (15) 5.6 (14) 7.5 (13) <0.001 
Routine occupation a 39.8 (1786) 44.0 (1135) 51.9 (669) 53.3 (478) 56.7 (351) 59.3 (275) 59.4 (208) 69.1 (169) 68.6 (119) <0.001 
Bottom quintile in total wealth b 12.1 (542) 16.2 (419) 24.3 (313) 24.1 (217) 29.2 (181) 33.6 (156) 38.6 (135) 37.9 (94) 42.2 (74) <0.001 
Living alone 22.0 (989) 29.3 (754) 38.5 (495) 37.4 (336) 41.1 (255) 48.1 (223) 51.7 (181) 53.8 (133) 69.4 (121) <0.001 
Current smoker 15.1 (677) 15.8 (407) 18.5 (238) 20.7 (186) 22.4 (139) 24.4 (113) 26.9 (94) 31.6 (78) 28.2 (49) <0.001 
≥2 alcoholic drinks a day  c 4.7 (201) 5.1 (124) 4.6 (57) 5.4 (46) 2.8 (17) 2.4 (11) 2.6 (9) 4.6 (11) 4.2 (7) 0.03 
Hardly ever physically active d          
  At a mild intensity 7.3 (328) 8.9 (231) 15.7 (202) 19.1 (171) 17.8 (111) 24.3 (113) 22.5 (78) 22.3 (55) 31.6 (55) <0.001 
  At a moderate intensity 10.2 (457) 16.9 (438) 26.8 (345) 34.4 (309) 33.3 (207) 40.7 (188) 42.1 (147) 43.9 (109) 41.4 (72) <0.001 
  At a vigorous intensity 53.8 (2417) 61.1 (1583) 70.8 (911) 72.1 (647) 76.8 (476) 79.5 (368) 79.4 (277) 81.5 (202) 83.9 (146) <0.001 
Difficulty in any ADL 8.5 (383) 16.8 (433) 28.1 (362) 37.2 (334) 38.0 (235) 42.9 (199) 44.2 (155) 44.9 (111) 52.8 (92) <0.001 
Difficulty in any IADL 8.2 (368) 16.7 (430) 31.2 (402) 35.7 (321) 42.7 (265) 48.9 (212) 48.1 (168) 47.3 (117) 58.3 (101) <0.001 
Diagnoses and health conditions           
   Hypertension  33.9 (1523) 38.3 (988) 39.6 (509) 42.9 (385) 45.0 (279) 43.3 (201) 42.9 (150) 44.6 (110) 42.7 (74) <0.001 
   Angina 6.1 (276) 9.1 (236) 12.8 (165) 13.0 (116) 16.5 (103) 14.7 (68) 16.0 (56) 19.1 (47) 19.7 (34) <0.001 
   Heart attack 4.2 (190) 5.8 (151) 6.4 (82) 8.0 (72) 9.2 (57) 7.8 (36) 9.9 (35) 10.1 (25) 9.2 (16) <0.001 
   Congenital heart condition 8.3 (371) 11.3 (291) 12.6 (162) 15.1 (135) 13.6 (84) 13.6 (63) 12.9 (45) 10.5 (26) 14.9 (26) <0.001 
   Stroke 2.2 (101) 3.8 (100) 6.0 (77) 6.4 (58) 7.0 (44) 7.2 (33) 7.6 (27) 7.5 (19) 7.7 (13) <0.001 
   Diabetes (type 1 and 2) 5.8 (259) 6.5 (167) 8.0 (103) 10.0 (89) 10.6 (66) 13.8 (64) 8.6 (30) 8.7 (22) 10.3 (18) <0.001 
   COPD 3.5 (155) 6.1 (156) 8.3 (107) 10.5 (95) 10.9 (67) 10.9 (51) 11.2 (39) 13.9 (35) 15.5 (27) <0.001 
   Asthma 9.4 (422) 9.7 (251) 12.3 (160) 15.5 (139) 16.3 (101) 16.8 (78) 18.2 (64) 16.1 (39) 23.0 (40) <0.001 
   Arthritis 21.9 (983) 32.9 (850) 39.1 (504) 42.4 (381) 46.5 (289) 51.0 (236) 52.9 (185) 45.4 (113) 51.7 (90) <0.001 
   Cancer 5.4 (242) 6.3 (161) 5.8 (74) 7.7 (69) 7.3 (45) 8.1 (37) 6.9 (24) 6.7 (17) 9.2 (16) <0.001 
   Depression 2.8 (125) 3.6 (92) 5.1 (65) 8.0 (72) 9.2 (57) 9.9 (46) 16.6 (58) 20.1 (51) 24.1 (42) <0.001 
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Antidepressant use e 2.0 (88) 3.9 (102) 6.0 (77) 7.1 (64) 8.4 (52) 8.9 (41) 12.1 (42) 15.5 (38) 14.4 (25) <0.001 
Memory index, M(SD) 17.22 (4.93) 16.56 (4.96) 15.37 (5.23) 15.15 (5.36) 14.94 (5.41) 14.58 (4.29) 14.13 (5.19) 14.30 (5.38) 13.69 (5.42) <0.001 
Executive function score 
M(SD)  
18.05 (4.11) 17.66 (4.18) 16.43 
(4.34) 
16.32 
(4.52) 
15.84 
(4.27) 
15.66 
(4.31) 
15.01 
(4.11) 
15.12 
(4.59) 
14.91 
(4.11) 
<0.001 
 
Data are % (N) of participants unless stated otherwise.  
 
a National Statistics Socio-economic Classification (NS-SEC) classification system: Higher managerial, administrative and professional 
occupations, Intermediate occupations, Routine and manual occupations; b Total wealth excludes debt and regular pension payments; c ≥2 
alcoholic drinks a day over the past year; d Hardly ever engaged in: mild; moderate; or vigorous physical activity; e Self-reported use of 
antidepressants in wave 0 comprising of: SSRI = Selective Serotonin Reuptake Inhibitors (British National Formulary [BNF] code: 40303) and 
Tricyclic antidepressants (BNF: 40301). A higher CES-D score indicates greater depressive symptoms. 
 
SD = Standard deviation; COPD: Chronic Obstructive Pulmonary Disorder. 
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Figure 1. Basic adjustment: age, sex and ethnicity (hatched bars); basic adjustment plus any condition or diagnosis: chronic diseases, circulatory 
disease, and cancers (black); full adjustment: basic adjustment plus socioeconomic position, living alone, any condition or diagnosis anti-
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depressant medication, and health behaviors (white). The reference group are participants with a score of zero; a higher score indicates more 
severe depressive symptoms.  
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Figure 2. Kaplan-Meier failure curve for all-cause mortality in people with a depressive symptom score of <2 or ≥2.
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1. Table S1. Hazard ratios (95% confidence intervals) for all-cause mortality according 
to depressive symptoms in 11,104 men and women 
2. Table S2. Hazard ratios (95% confidence intervals) for all-cause mortality in fully 
adjusted model according to depressive symptoms in 11,104 men and women 
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6. Figure S1. Kaplan-Meier survival curve for all-cause mortality according to severity 
of depressive symptoms (higher CES-D score indicates greater depressive symptoms). 
7. Items of the 8-item version of the Center of Epidemiological Studies-Depression 
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Table 1. Hazard ratios (95% confidence intervals) for all-cause mortality according to depressive symptoms in 11,104 men and women 
Model  Depressive symptoms (CES-D score)   
 0 1 2 3 4 5 6 7 8 P-value 
for trend 
Per SD 
increase 
Basic  model a 1 (ref) 1.11 
(0.98, 1.25) 
1.59 
(1.40, 1.82) 
1.78 
(1.54, 2.06) 
1.80  
(1.52, 2.13) 
2.10 
(1.74, 2.53) 
1.81 
(1.45, 2.23) 
1.97 
(1.52, 2.55) 
2.27 
(1.69, 3.04) 
<0.001 1.26 
(1.22,1.31) 
Basic  model + 
socioeconomic position 
b 
1 1.08 
(0.96, 1.22) 
1.47 
(1.29, 1.68) 
1.63 
(1.41, 1.89) 
1.65  
(1.40, 1.96) 
1.85 
(1.53, 2.23) 
1.55 
(1.25, 1.92) 
1.69 
(1.30, 2.19) 
1.89 
(1.40, 2.53) 
<0.001 1.20 
(1.16,1.25) 
Basic  model + living 
alone 
1 1.08 
(0.96, 1.22) 
1.53 
(0.96, 1.22) 
1.71 
(1.48, 1.98) 
1.71  
(1.44, 2.02) 
1.97 
(1.63, 2.37) 
1.65 
(1.33, 1.05) 
1.82 
(1.40, 2.36) 
1.92 
(1.43, 2.58) 
<0.001 1.23 
(1.18,1.28) 
Basic  model + 
antidepressant 
medication c 
1 1.11 
(0.98, 1.25) 
1.58 
(1.39, 1.81) 
1.76 
(1.52, 2.04) 
1.78  
(1.50, 2.10) 
2.07 
(1.72, 2.49) 
1.77 
(1.43, 2.19) 
1.89 
(1.49, 2.45) 
2.22 
(1.66, 2.98) 
<0.001 1.25 
(1.21,1.30) 
Basic  model + health 
behaviours d 
1 1.01 
(0.90, 1.14) 
1.27 
(1.12, 1.46) 
1.31 
(1.13, 1.52) 
1.35  
(1.14, 1.61) 
1.46 
(1.21, 1.77) 
1.17 
(0.94, 1.46) 
1.23 
(0.95, 1.60) 
1.40 
(1.04, 1.89) 
<0.001 1.10 
(1.06,1.15) 
Basic  model + any 
mobility impairment 
1 1.02 
(0.91, 1.15) 
1.30 
(1.14, 1.49) 
1.36 
(1.17, 1.59) 
1.35  
(1.14, 1.62) 
1.53 
(1.26, 1.85) 
1.28 
(1.03, 1.59) 
1.35 
(1.04, 1.76) 
1.42 
(1.06, 1.93) 
<0.001 1.12 
(1.07,1.17) 
Basic  model + tests of 
cognitive function e 
1 1.07 
(0.94, 1.21) 
1.41 
(1.24, 1.61) 
1.54 
(1.33, 1.79) 
1.50  
(1.27, 1.78) 
1.69 
(1.40, 2.04) 
1.43 
(1.15, 1.77) 
1.49 
(1.15, 1.94) 
1.72 
(1.28, 2.31) 
<0.001 1.17 
(1.12,1.21) 
Basic  model + chronic 
somatic conditions f 
1 1.09 
(0.96, 1.23) 
1.50 
(1.32, 1.72) 
1.67 
(1.44, 1.93) 
1.69  
(1.43, 2.00) 
1.88 
(1.56, 2.27) 
1.65 
(1.33, 2.05) 
1.80 
(1.39, 2.33) 
2.10 
(1.57, 2.89) 
<0.001 1.23 
(1.18,1.28) 
Basic  model + 
circulatory disease and 
risk factors g 
1 1.08 
(0.95, 1.21) 
1.52 
(1.32, 1.73) 
1.67 
(1.44, 1.94) 
1.69  
(1.43, 2.00) 
1.91 
(1.58, 2.30) 
1.56 
(1.26, 1.94) 
1.81 
(1.40, 2.36) 
2.06 
(1.54, 2.77) 
<0.001 1.22 
(1.18,1.27) 
Basic  model + all 
illnesses and conditions 
1 1.05 
(0.93, 1.19) 
1.43 
(1.26, 1.64) 
1.59 
(1.38, 1.85) 
1.60  
(1.35, 1.90) 
1.77 
(1.46, 2.14) 
1.49 
(1.20, 1.85) 
1.70 
(1.31, 2.21) 
1.90 
(1.42, 2.55) 
<0.001 1.20 
(1.15,1.25) 
Fully adjusted without 
tests of cognitive 
function 
1 0.94 
(0.83, 1.06) 
1.07 
(0.93, 1.22) 
1.12 
(0.96, 1.31) 
1.11  
(0.93, 1.32) 
1.12 
(0.92, 1.36) 
0.88 
(0.70, 1.10) 
0.92 
(0.70, 1.21) 
0.96 
(0.71, 1.30) 
0.20 1.00 
(0.96,1.05) 
Fully adjusted 1 0.94 
(0.83, 1.06) 
1.03 
(0.90, 1.19) 
1.07 
(0.92, 1.25) 
1.03  
(0.86, 1.23) 
1.05 
(0.86, 1.27) 
0.82 
(0.65, 1.02) 
0.84 
(0.64, 1.11) 
0.87 
(0.64, 1.18) 
0.25 0.98 
(0.93,1.02) 
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a Basic model is adjusted for age, sex and ethnicity; b Socioeconomic position comprises occupational social class according to the National 
Statistics Socio-economic Classification (NS-SEC) and total wealth (excluding debt and regular pension payments); c Self-reported use of 
antidepressants in wave 0 comprising of: SSRI = Selective Serotonin Reuptake Inhibitors (BNF: 40303) and Tricyclic antidepressants (BNF: 
40301); d Health behaviours comprise smoking status, alcohol intake (per year) and physical activity; e Tests of cognitive function were on: 
memory and executive function; f Chronic conditions were COPD and other chronic respiratory conditions, asthma, diabetes (types 1 and 2) and 
arthritis; g Circulatory disease and risk factors comprise of hypertension, previous heart attack, stroke, angina, and congenital heart conditions. 
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Table 2. Hazard ratios (95% confidence intervals) for all-cause mortality according to 
depressive symptoms and fully adjusted (n = 11,104) 
Factor Adjusted hazard ratio P value 
Depressive symptom (CES-D) score   
0 (lowest) 1 (reference)  
1  0.94 (0.83, 1.06) 0.31 
2  1.03 (0.90, 1.19) 0.62 
3  1.07 (0.92, 1.25) 0.37 
4  1.03 (0.86, 1.23) 0.73 
5  1.05 (0.86, 1.28) 0.65 
6  0.82 (0.65, 1.02) 0.08 
7  0.84 (0.64, 1.11) 0.22 
8 (highest) 0.87 (0.64, 1.18) 0.36 
  0.25 (trend) 
Sex (male) 0.59 (0.53, 0.64) <0.001 
Age, years a 1.06 (1.06, 1.07) <0.001 
Ethnic group   
  Non-white  1 (reference)  
  White 0.59 (0.53, 0.64) <0.001 
NSSEC social class   
  Routine and manual 1 (reference)  
  Intermediate 0.98 (0.86, 1.11) 0.72 
  Higher managerial  
 
0.87 (0.77, 0.97) 0.02 
Quintiles of total wealth   
  1 (lowest) 1 (reference)  
  2 1.00 (0.89, 1.13) 0.97 
  3 0.97 (0.85, 1.10) 0.61 
  4 0.90 (0.78, 1.04) 0.17 
  5 (highest) 0.87 (0.74, 1.01) 0.07 
  0.31 (trend) 
Living alone 
 
1.33 (1.21, 1.46) <0.001 
Smoking status   
  Never 1 (reference)  
  Ex-smoker 1.24 (1.12, 1.38) <0.001 
Current smoker 1.55 (1.36, 1.77) <0.001 
Frequency of drinking alcohol in past 
year 
  
Twice a day or more 1 (reference)  
Daily or almost daily 0.91 (0.75, 1.12) 0.38 
Once or twice a week 0.78 (0.64, 0.95) 0.01 
Once or twice a month 0.68 (0.54, 0.86) 0.001 
Special occasions only 0.90 (0.73, 1.10) 0.29 
Never consume 0.95 (0.77, 1.17) 0.64 
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  <0.001 
(trend) Mild intensity physical activity   
  More than once a week 1 (reference)  
  Once a week 0.98 (0.77, 1.24) 0.85 
  One to three times a week 1.06 (0.84, 1.33) 0.63 
  Hardly ever, never 1.39 (1.18, 1.63) <0.001 
  <0.001 
(trend) Moderate intensity physical activity   
  More than once a week 1 (reference)  
  Once a week 1.07 (0.93, 1.22) 0.35 
  One to three times a week 1.10 (0.92, 1.32) 0.28 
  Hardly ever, never 1.42 (1.25, 1.60) <0.001 
  <0.001 
(trend) Vigorous intensity physical activity   
  More than once a week 1 (reference)  
  Once a week 1.03 (0.90, 1.17) 0.67 
  One to three times a week 1.15 (0.94, 1.40) 0.17 
  Hardly ever, never 1.06 (0.93, 1.19) 0.14 
  0.74 (trend) 
Memory index a 0.95 (0.94, 0.96) <0.001 
Executive function score a 0.96 (0.94, 0.97) <0.001 
Chronic conditions   
   COPD 1.53 (1.35, 1.75) <0.001 
   Asthma 0.92 (0.81, 1.05) 0.23 
   Arthritis 0.94 (0.85, 1.03) 0.15 
   Diabetes (type 1 and 2) 1.21 (1.06, 1.38) 0.005 
Cardiovascular disease   
   Hypertension 1.05 (0.96, 1.16) 0.21 
   Previous heart attack  1.04 (0.90, 1.21) 0.56 
   Stroke 1.11 (0.96, 1.28) 0.17 
   Angina 1.06 (0.94, 1.20) 0.33 
   Congenital heart disease 1.40 (1.25, 1.56) <0.001 
Cancer 1.95 (1.71, 2.23) <0.001 
Mobility impairments   
   Any difficulty in a ADL 1.13 (1.01, 1.26) 0.03 
   Any difficulty in a IADL 1.32 (1.18, 1.47) <0.001 
Antidepressant use 0.99 (0.82, 1.19) 0.88 
a Modelled as a continuous term.  
Abbreviations: NS-SEC: National Statistics Socio-economic Classification; COPD: Chronic 
obstructive pulmonary disorder; ADL: Activities of daily living; IADL: Instrumental 
activities of daily living 
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Table 3. Hazard ratios (95% confidence intervals) for all-cause mortality according to 
depressive symptoms in 10,131 participants with complete data 
Model Depressive symptoms (CES-D score)   
 0 1 2 3 4 5 6 7 8 P-
valu
e 
for 
tren
d 
Per 
SD 
incre
ase 
Basic  model 
a 
1 
(re
f) 
1.13 
(0.99, 
1.28) 
1.53 
(1.33, 
1.76) 
1.76 
(1.52, 
2.06) 
1.70  
(1.42, 
2.03) 
1.89 
(1.52, 
2.34) 
2.10 
(1.69, 
2.62) 
1.98 
(1.49, 
2.64) 
2.05 
(1.49, 
2.83) 
<0.0
01 
1.25 
(1.21,
1.31) 
Basic  model + 
socioeconomic 
position b 
1 1.10 
(0.97, 
1.24) 
1.42 
(1.23, 
1.63) 
1.62 
(1.39, 
1.88) 
1.55  
(1.30, 
1.85) 
1.67 
(1.35, 
2.07) 
1.79 
(1.44, 
2.23) 
1.69 
(1.27, 
2.26) 
1.70 
(1.23, 
2.35) 
<0.0
01 
1.20 
(1.15,
1.25) 
Basic  model + 
living alone 
1 1.10 
(0.97, 
1.24) 
1.47 
(1.28, 
1.69) 
1.70 
(1.46, 
1.98) 
1.61  
(1.34, 
1.93) 
1.77 
(1.43, 
2.19) 
1.93 
(1.55, 
2.41) 
1.84 
(1.38, 
2.45) 
1.73 
(1.25, 
2.39) 
<0.0
01 
1.22 
(1.17,
1.27) 
Basic  model + 
antidepressant 
medication c 
1 1.12 
(0.99, 
1.27) 
1.52 
(1.32, 
1.75) 
1.75 
(1.51, 
2.04) 
1.68  
(1.40, 
2.01) 
1.86 
(1.50, 
2.30) 
2.06 
(1.65, 
2.56) 
1.89 
(1.41, 
2.52) 
2.01 
(1.46, 
2.77) 
<0.0
01 
1.25 
(1.20,
1.30) 
Basic  model + 
health 
behaviours d 
1 1.02 
(0.90, 
1.16) 
1.22 
(1.06, 
1.41) 
1.31 
(1.11, 
1.53) 
1.29  
(1.08, 
1.55) 
1.35 
(1.08, 
1.67) 
1.39 
(1.11, 
1.73) 
1.23 
(0.92, 
1.65) 
1.31 
(0.94, 
1.81) 
<0.0
01 
1.10 
(1.06,
1.15) 
Basic  model + 
any mobility 
impairment 
1 1.05 
(0.92, 
1.19) 
1.25 
(1.09, 
1.44) 
1.38 
(1.18, 
1.61) 
1.29  
(1.07, 
1.55) 
1.41 
(1.13, 
1.75) 
1.48 
(1.18, 
1.85) 
1.39 
(1.04, 
1.86) 
1.31 
(0.95, 
1.82) 
<0.0
01 
1.12 
(1.07,
1.17) 
Basic  model + 
tests of 
cognitive 
function e 
1 1.09 
(0.97, 
1.24) 
1.37 
(1.19, 
1.57) 
1.55 
(1.33, 
1.80) 
1.42  
(1.18, 
1.69) 
1.59 
(1.28, 
1.96) 
1.66 
(1.33, 
2.07) 
1.55 
(1.16, 
2.07) 
1.56 
(1.13, 
2.16) 
<0.0
01 
1.16 
(1.12,
1.21) 
Basic  model + 
chronic 
conditions f 
1 1.10 
(0.97, 
1.25) 
1.43 
(1.24, 
1.65) 
1.65 
(1.42, 
1.93) 
1.58  
(1.32, 
1.90) 
1.66 
(1.33, 
2.05) 
1.89 
(1.51, 
2.36) 
1.77 
(1.33, 
2.37) 
1.89 
(1.37, 
2.60) 
<0.0
01 
1.21 
(1.16,
1.26) 
Basic  model + 
circulatory 
disease and 
risk factors g 
1 1.08 
(0.95, 
1.21) 
1.52 
(1.32, 
1.73) 
1.67 
(1.44, 
1.94) 
1.69  
(1.43, 
2.00) 
1.91 
(1.58, 
2.30) 
1.56 
(1.26, 
1.94) 
1.81 
(1.40, 
2.36) 
2.06 
(1.54, 
2.77) 
<0.0
01 
1.22 
(1.17,
1.27) 
Basic  model + 
all illnesses 
and conditions 
1 1.05 
(0.93, 
1.19) 
1.43 
(1.26, 
1.64) 
1.59 
(1.38, 
1.85) 
1.60  
(1.35, 
1.90) 
1.77 
(1.46, 
2.14) 
1.49 
(1.20, 
1.85) 
1.70 
(1.31, 
2.21) 
1.90 
(1.42, 
2.55) 
<0.0
01 
1.19 
(1.14,
1.24) 
Fully adjusted 
without tests of 
cognitive 
function 
1 0.94 
(0.83, 
1.06) 
1.07 
(0.93, 
1.22) 
1.12 
(0.96, 
1.31) 
1.11  
(0.93, 
1.32) 
1.12 
(0.92, 
1.36) 
0.88 
(0.70, 
1.10) 
0.92 
(0.70, 
1.21) 
0.96 
(0.71, 
1.30) 
0.20 1.00 
(0.95,
1.05) 
Fully adjusted 1 0.96 
(0.84, 
1.09) 
0.99 
(0.85, 
1.14) 
1.06 
(0.90, 
1.24) 
0.95  
(0.79, 
1.15) 
0.95 
(0.76, 
1.19) 
0.96 
(0.76, 
1.21) 
0.84 
(0.62, 
1.13) 
0.79 
(0.57, 
1.10) 
0.80 0.97 
(0.93,
1.02) 
a Basic model is adjusted for age, sex and ethnicity; b Socioeconomic position comprises 
occupational social class according to the National Statistics Socio-economic Classification 
(NS-SEC) and total wealth (excluding debt and regular pension payments); c Self-reported 
use of antidepressants in wave 0 comprising of: SSRI = Selective Serotonin Reuptake 
Inhibitors (BNF: 40303) and Tricyclic antidepressants (BNF: 40301); d Health behaviours 
comprise smoking status, alcohol intake (per year) and physical activity; e Tests of cognitive 
function were on: memory and executive function; f Chronic conditions were COPD and 
other chronic respiratory conditions, asthma, diabetes (types 1 and 2) and arthritis; g 
Circulatory disease and risk factors comprise of hypertension, previous heart attack, stroke, 
angina, and congenital heart conditions. 
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Table 4. Hazard ratios (95% confidence intervals) for all-cause mortality according to 
depressive symptoms after excluding somatic symptoms from score (n = 11,104) 
Model Depressive symptoms (CES-D score)   
 0 1 2 3 4 5 P-
valu
e for 
tren
d 
Per 
SD 
incre
ase 
Basic  model a 1 
(r
ef
) 
1.31 
(1.17, 
1.47) 
1.45 
(1.26, 
1.66) 
1.66 
(1.41, 
1.96) 
1.59  
(1.30, 
1.96) 
1.84 
(1.47, 
2.30) 
<0.00
1 
1.15 
(1.11, 
1.18) 
Basic  model + 
socioeconomic 
position b 
1 1.21 
(1.08, 
1.36) 
1.35 
(1.17, 
1.55) 
1.43 
(1.21, 
1.69) 
1.40  
(1.15, 
1.73) 
1.57 
(1.26, 
1.97) 
<0.00
1 
1.10 
(1.07, 
1.14) 
Basic  model + 
living alone 
1 1.23 
(1.10, 
1.38) 
1.37 
(1.19, 
1.57) 
1.50 
(1.26, 
1.77) 
1.47  
(1.20, 
1.80) 
1.58 
(1.26, 
1.98) 
<0.00
1 
1.11 
(1.08, 
1.14) 
Basic  model + 
antidepressant 
medication c 
1 1.30 
(1.16, 
1.46) 
1.43 
(1.24, 
1.64) 
1.63 
(1.38, 
1.92) 
1.53  
(1.24, 
1.88) 
1.80 
(1.44, 
2.25) 
<0.00
1 
1.14 
(1.11, 
1.17) 
Basic  model + 
health behaviours 
d 
1 1.13 
(1.01, 
1.27) 
1.17 
(1.02, 
1.36) 
1.26 
(1.06, 
1.48) 
1.20  
(0.97, 
1.48) 
1.22 
(0.97, 
1.52) 
0.01 1.05 
(1.02, 
1.08) 
Basic  model + 
any mobility 
impairment 
1 1.18 
(1.05, 
1.32) 
1.22 
(1.06, 
1.41) 
1.34 
(1.13, 
1.59) 
1.24  
(1.01, 
1.53) 
1.31 
(1.04, 
1.64) 
0.003 1.07 
(1.03, 
1.10) 
Basic  model + 
chronic conditions 
e 
1 1.27 
(1.14, 
1.43) 
1.38 
(1.20, 
1.59) 
1.56 
(1.32, 
1.85) 
1.42  
(1.16, 
1.75) 
1.74 
(1.39, 
2.18) 
<0.00
1 
1.12 
(1.09, 
1.16) 
Basic  model + 
tests of cognitive 
function e 
1 1.19 
(1.06, 
1.33) 
1.25 
(1.09, 
1.44) 
1.39 
(1.17, 
1.64) 
1.30  
(1.06, 
1.60) 
1.46 
(1.16, 
1.83) 
<0.00
1 
1.09 
(1.05, 
1.12) 
Basic  model + 
circulatory 
disease and risk 
factors f 
1 1.27 
(1.13, 
1.42) 
1.42 
(1.23, 
1.63) 
1.55 
(1.31, 
1.83) 
1.46  
(1.19, 
1.79) 
1.67 
(1.33, 
2.09) 
<0.00
1 
1.12 
(1.09, 
1.16) 
Basic  model + all 
illnesses and 
conditions 
1 1.22 
(1.09, 
1.37) 
1.37 
(1.19, 
1.58) 
1.51 
(1.27, 
1.78) 
1.31  
(1.07, 
1.62) 
1.63 
(1.30, 
2.04) 
<0.00
1 
1.11 
(1.08, 
1.14) 
Fully adjusted 
without tests of 
cognitive function 
1 1.27 
(1.14, 
1.43) 
1.38 
(1.20, 
1.59) 
1.56 
(1.32, 
1.85) 
1.42  
(1.16, 
1.75) 
1.74 
(1.39, 
2.18) 
<0.00
1 
0.99 
(0.96, 
1.03) 
Fully adjusted 1 0.97 
(0.86, 
1.09) 
1.00 
(0.86, 
1.15) 
0.96 
(0.81, 
1.14) 
0.88  
(0.71, 
1.08) 
0.87 
(0.69, 
1.11) 
0.75 0.98 
(0.95, 
1.01) 
a Basic model is adjusted for age, sex and ethnicity; b Socioeconomic position comprises 
occupational social class according to the National Statistics Socio-economic Classification 
(NS-SEC) and total wealth (excluding debt and regular pension payments); c Self-reported 
use of antidepressants in wave 0 comprising of: SSRI = Selective Serotonin Reuptake 
Inhibitors (BNF: 40303) and Tricyclic antidepressants (BNF: 40301); d Health behaviours 
comprise smoking status, alcohol intake (per year) and physical activity; e Tests of cognitive 
function were on: memory and executive function; f Chronic conditions were COPD and 
other chronic respiratory conditions, asthma, diabetes (types 1 and 2) and arthritis; g 
Circulatory disease and risk factors comprise of hypertension, previous heart attack, stroke, 
angina, and congenital heart conditions. 
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Table 5. Hazard ratios (95% confidence intervals) for all-cause mortality according to 
depressive symptoms excluding deaths in first 5 years after wave one (n = 10,122) 
Model Depressive symptoms (CES-D score)   
 0 1 2 3 4 5 6 7 8 P-
valu
e 
for 
tren
d 
Per 
SD 
incre
ase 
Basic  model 
a 
1 
(re
f) 
1.00 
(0.86, 
1.17) 
1.48 
(1.25, 
1.76) 
1.67 
(1.38, 
2.02) 
1.50  
(1.19, 
1.89) 
1.75 
(1.35, 
2.28) 
1.58 
(1.18, 
2.11) 
1.73 
(1.21, 
2.47) 
1.66 
(1.05, 
2.59) 
<0.0
01 
1.20 
(1.14,
1.26) 
Basic  model + 
socioeconomic 
position b 
1 0.98 
(0.84, 
1.15) 
1.38 
(1.15, 
1.64) 
1.55 
(1.28, 
1.88) 
1.39  
(1.11, 
1.76) 
1.57 
(1.20, 
2.03) 
1.39 
(1.04, 
1.86) 
1.51 
(1.06, 
2.16) 
1.42 
(0.91, 
2.23) 
<0.0
01 
1.15 
(1.09,
1.21) 
Basic  model + 
living alone 
1 0.98 
(0.84, 
1.15) 
1.42 
(1.19, 
1.68) 
1.61 
(1.33, 
1.95) 
1.44  
(1.14, 
1.81) 
1.64 
(1.27, 
2.14) 
1.46 
(1.09, 
1.94) 
1.61 
(1.13, 
2.30) 
1.42 
(0.90, 
2.22) 
<0.0
01 
1.17 
(1.11,
1.23) 
Basic  model + 
antidepressant 
medication c 
1 1.00 
(0.85, 
1.17) 
1.47 
(1.24, 
1.75) 
1.65 
(1.36, 
2.00) 
1.48  
(1.17, 
1.87) 
1.73 
(1.33, 
2.24) 
1.55 
(1.16, 
2.07) 
1.65 
(1.15, 
2.37) 
1.62 
(1.04, 
2.54) 
<0.0
01 
1.19 
(1.13,
1.26) 
Basic  model + 
health 
behaviours d 
1 0.93 
(0.80, 
1.09) 
1.24 
(1.04, 
1.48) 
1.32 
(1.08, 
1.60) 
1.19  
(0.94, 
1.51) 
1.32 
(1.02, 
1.72) 
1.12 
(0.84, 
1.51) 
1.20 
(0.83, 
1.71) 
1.09 
(0.69, 
1.71) 
0.01 1.07 
(1.02,
1.14) 
Basic  model + 
any mobility 
impairment 
1 0.94 
(0.79, 
1.10) 
1.25 
(1.05, 
1.49) 
1.33 
(1.09, 
1.62) 
1.17  
(0.93, 
1.49) 
1.35 
(1.03, 
1.76) 
1.17 
(0.87, 
1.57) 
1.25 
(0.87, 
1.80) 
1.10 
(0.70, 
1.74) 
0.01 1.08 
(1.02,
1.14) 
Basic  model + 
tests of 
cognitive 
function e 
1 0.96 
(0.82, 
1.13) 
1.31 
(1.10, 
1.56) 
1.47 
(1.22, 
1.79) 
1.26  
(1.00, 
1.59) 
1.44 
(1.11, 
1.88) 
1.24 
(0.93, 
1.67) 
1.36 
(0.95, 
1.95) 
1.28 
(0.82, 
2.00) 
<0.0
01 
1.12 
(1.06,
1.18) 
Basic  model + 
chronic 
conditions f 
1 0.97 
(0.83, 
1.13) 
1.41 
(1.18, 
1.67) 
1.58 
(1.30, 
1.92) 
1.40  
(1.11, 
1.77) 
1.59 
(1.22, 
2.07) 
1.38 
(1.03, 
1.85) 
1.57 
(1.10, 
2.24) 
1.49 
(0.95, 
2.33) 
<0.0
01 
1.16 
(1.10,
1.23) 
Basic  model + 
circulatory 
disease and 
risk factors g 
1 0.97 
(0.83, 
1.13) 
1.41 
(1.18, 
1.67) 
1.58 
(1.30, 
1.92) 
1.40  
(1.11, 
1.77) 
1.59 
(1.22, 
2.07) 
1.38 
(1.03, 
1.85) 
1.57 
(1.10, 
2.24) 
1.49 
(0.95, 
2.33) 
<0.0
01 
1.16 
(1.10,
1.22) 
Basic  model + 
all illnesses 
and conditions 
1 0.95 
(0.81, 
1.12) 
1.33 
(1.12, 
1.59) 
1.51 
(1.24, 
1.83) 
1.34  
(1.06, 
1.70) 
1.46 
(1.12, 
1.91) 
1.31 
(0.97, 
1.75) 
1.46 
(1.02, 
2.10) 
1.40 
(0.89, 
2.19) 
<0.0
01 
1.14 
(1.08,
1.20) 
Fully adjusted 
without tests of 
cognitive 
function 
1 0.86 
(0.74, 
1.01) 
1.03 
(0.86, 
1.24) 
1.12 
(0.91, 
1.37) 
0.97  
(0.77, 
1.24) 
1.01 
(0.77, 
1.32) 
0.85 
(0.62, 
1.15) 
0.87 
(0.60, 
1.26) 
0.74 
(0.46, 
1.18) 
0.25 0.98 
(0.92,
1.04) 
Fully adjusted 1 0.86 
(0.73, 
1.00) 
0.99 
(0.83, 
1.19) 
1.07 
(0.87, 
1.31) 
0.91  
(0.71, 
1.16) 
0.95 
(0.72, 
1.25) 
0.77 
(0.57, 
1.05) 
0.82 
(0.56, 
1.19) 
0.67 
(0.42, 
1.06) 
0.19 0.95 
(0.90,
1.01) 
a Basic model is adjusted for age, sex and ethnicity; b Socioeconomic position comprises 
occupational social class according to the National Statistics Socio-economic Classification 
(NS-SEC) and total wealth (excluding debt and regular pension payments); c Self-reported 
use of antidepressants in wave 0 comprising of: SSRI = Selective Serotonin Reuptake 
Inhibitors (BNF: 40303) and Tricyclic antidepressants (BNF: 40301); d Health behaviours 
comprise smoking status, alcohol intake (per year) and physical activity; e Tests of cognitive 
function were on: memory and executive function; f Chronic conditions were COPD and 
other chronic respiratory conditions, asthma, diabetes (types 1 and 2) and arthritis; g 
Circulatory disease and risk factors comprise of hypertension, previous heart attack, stroke, 
angina, and congenital heart conditions. 
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Figure S1. Kaplan-Meier survival curve for all-cause mortality according to severity of 
depressive symptoms (higher CES-D score indicates greater depressive symptoms).  
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Items of the 8-item version of the Center of Epidemiological Studies-Depression Scale. 
Much of the time during the past week... 
Yes = 1; No = 0. Total score range from  0 to 8. 
 
... did you feel depressed? 
... did you feel everything you did was an effort? * 
... was your sleep restless? * 
... were you happy? 
... did you feel lonely? 
... did you enjoy life? 
... did you feel sad? 
... were you unable to get going? * 
 
* Items assessing somatic symptoms 
